HLA-DQB1 antibody (N-Term)

Catalog No. ABIN1881422

There are 4+ publications for this product available. The Rabbit Polyclonal anti-HLA-DQB1 antibody is suitable to detect HLA-DQB1 in samples from Human. It has been validated for WB.

Quick Overview for HLA-DQB1 antibody (N-Term) (ABIN1881422)

Target: HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ beta 1 (HLA-DQB1))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This HLA-DQB1 antibody is un-conjugated

Application: Western Blotting (WB)

Product Details anti-HLA-DQB1 Antibody

Binding Specificity: AA 13-39, N-Term

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogen: This HLA-DQB1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 13-39 amino acids from the N-terminal region of human HLA-DQB1.

Isotype: Ig Fraction

Application Details

Application Notes: WB: 1:1000

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: Purified polyclonal antibody supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Expiry Date: 6 months

References for anti-HLA-DQB1 antibody (ABIN1881422)

Larhammar, Hyldig-Nielsen, Servenius, Andersson, Rask, Peterson: "Exon-intron organization and complete nucleotide sequence of a human major histocompatibility antigen DC beta gene." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 80, Issue 23, pp. 7313-7, (1984) (PubMed).

Boss, Strominger: "Cloning and sequence analysis of the human major histocompatibility complex gene DC-3 beta." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 81, Issue 16, pp. 5199-203, (1984) (PubMed).

Larhammar, Andersson, Andersson, Bill, Böhme, Claesson, Denaro, Emmoth, Gustafsson, Hammarling: "Molecular analysis of human class II transplantation antigens and their genes." in: Human immunology, Vol. 8, Issue 1, pp. 95-103, (1983) (PubMed).

Larhammar, Schenning, Gustafsson, Wiman, Claesson, Rask, Peterson: "Complete amino acid sequence of an HLA-DR antigen-like beta chain as predicted from the nucleotide sequence: similarities with immunoglobulins and HLA-A, -B, and -C antigens." in: Proceedings of the National Academy of Sciences of the United States of America, Vol. 79, Issue 12, pp. 3687-91, (1982) (PubMed).

Target Details for HLA-DQB1

Target: HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ beta 1 (HLA-DQB1))

Alternative Name: HLA-DQB1

Background: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form an heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal miroenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.

Molecular Weight: 29991

NCBI Accession: NP_001230891, NP_002114

UniProt: P01920

Pathways: TCR Signaling, Production of Molecular Mediator of Immune Response, Cancer Immune Checkpoints, Human Leukocyte Antigen (HLA) in Adaptive Immune Response